REC Reference	IRAS Number	Trial	Date of first recruit	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready to Start	Reason for Delay	Reasons for not achieving the 70 day benchmark
16/LO/0675	147355	CC-486 (oral Azacitidine alone and with Durvalumab (MEDI4736) in myelodysplastic syndromes.		No	29/06/2016	07/07/2016	09/06/2016	03/10/2016	06/10/2016	–	16/01/2017	Sponsor Delays	Delays due to lack of availability of lab manual. Costings not agreed with Sponsor. HRA approval delayed. Document set sent early by sponsor. Site initiation arranged by sponsor 31/10/16. Study not open internationally though due to amendment which was approved 23/12/2016 and trial could not open until run-in phase completed. Open to recruitment 16/01/2017.
16/SC/0109	163094	UK STAR	09/03/2017	No	19/09/2016	16/11/2016	16/11/2016	16/11/2016	23/11/2016	–	30/11/2016	Both Sponsor/NHS provider	Delay receiving HRA Approval Letter for addition of site leaving 1 week to recruit to benchmark. No suitable patients identified. Trauma led study.
16/NW/0517	188554	Myeloma XII (ACCoRd trial) Version 1.0		No	02/08/2016	27/10/2016	27/10/2016	27/10/2016	29/11/2016	–	29/03/2017	Sponsor Delays	Initial delay in IMP availability for all sites. Pharmacy green light given 29/03/2017.
16/NE/0238	204031	The BHF SENIOR-RITA TRIAL	29/06/2017	No	25/07/2016	18/08/2016	08/08/2016	04/01/2017	11/01/2017	–	27/01/2017	Sponsor Delays	Sponsor amended costings and CTA delaying signing.
14/SC/1290	141516	TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia	02/03/2017	No	01/07/2016	26/07/2016	23/08/2016	26/07/2016	04/01/2017	–	20/01/2017	Sponsor Delays	Initial delays from Sponsor due to their Trial Manager leaving which meant a delay to SIV until 20th January 17. Green Light delayed as no IMP from sponsor and pharmacy site file not received till 20.01.17. Still awaiting IMP end of January 17.
11/LO/2019	76882	TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer		Site Not Confirmed	31/10/2016	09/03/2017	15/06/2016	Site Not Confirmed	Site Not Confirmed	Site declined to participate		Site declined to participate	Site declined - confirmed no capacity and capability
11/LO/1915	92260	The PACE Study	10/05/2017	No	17/12/2015	18/01/2017	19/08/2016	07/06/2016	25/05/2016	–	09/03/2017	Neither Sponsor/NHS Provider	Rare disease
14/LO/0259	134883	RE-AKT		No	16/09/2016	23/01/2017	30/06/2016	11/05/2017	28/04/2017	–	08/06/2017	Sponsor Delays	Delay in receiving contract and obtaining sign off from sponsor and delay in receiving trial medication. Rare patient cohort.
14/NE/1144	154101	The NAtional Trial of Tonsillectomy IN Adults (NATTINA)	23/05/2017	No	12/11/2015	10/01/2017	30/06/2016	16/01/2017	30/01/2017	–	18/01/2017	NHS Provider	Limited number of patients with condition. No patients matching criteria seen.
15/EM/0095	166503	ACELARATE: Acelarin first line randomised pancreatic study	02/06/2017	No	18/06/2015	19/12/2016	15/06/2016	01/03/2017	06/03/2017	–	09/03/2017	Sponsor Delays	Delay in pharmacy green light due to sponsor identifying IMP transport arrangements and CTA delays.
16/EE/0357	206051	OPTIPARK	12/06/2017	No	08/11/2016	06/12/2016	31/10/2016	20/02/2017	01/03/2017	–	09/03/2017	Both Sponsor/NHS provider	CRO not available for SIV & capacity and capability issues at site.
16/SC/0502	199315	The ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients		Site Not Confirmed	16/09/2016	01/11/2016	–	Site Not Confirmed	Site Not Confirmed	Site declined to participate	N/A	Site declined to participate	Site declined - confirmed no capacity and capability.
16/NE/0384	209045	PARADISE-MI		No	22/12/2016	23/01/2017	05/01/2017	31/05/2017	07/06/2017	–	Awaiting	Sponsor Delays	Delays in receiving signed contract from sponsor and also shortage of IMP. SIV scheduled 28/07/2017.
16/WM/0010	169512	A phase II trial of pembrolizumab in NSCLC PS2 patients		No	04/08/2016	05/04/2017	28/06/2016	21/06/2017	14/06/2017	–	Awaiting	NHS Provider	Delay in receiving pathology and radiology approvals including RECIST reporting, Irmer8 and ARSAC licence. SIV scheduled 04/08/2017.